Home Ingredients Glabridin (Licorice Isoflavone)
CardiovascularMetabolic HealthHair, Skin & NailsAntioxidant

Glabridin (Licorice Isoflavone)

Glycyrrhiza glabra L. — isolated isoflavonoid
Evidence Level
Limited
3 Clinical Trials
7 Documented Benefits
2/5 Evidence Score

Glabridin is an isoflavonoid specific to Glycyrrhiza glabra L. (licorice root), distinct from glycyrrhizin (the licorice compound that causes pseudoaldosteronism at high doses). It is the most-studied licorice flavonoid, with multi-target activity across lipid, glucose, and skin pigmentation pathways. At 250 mg/day, plasma LDL oxidation was reduced 20%, an atheroprotective mechanism distinct from cholesterol-lowering. Smaller trials in type 2 diabetes and metabolic syndrome at 300 mg/day showed reductions in cholesterol, glycated hemoglobin, and visceral fat. Skin applications use the topical route: glabridin inhibits tyrosinase far more potently than hydroquinone in vitro and reduces UV-induced hyperpigmentation in clinical studies. The key limitation is only about 7.5% oral bioavailability, so branded delivery systems like Glavonoid® (MCT oil emulsion) are preferable for systemic effects. The honest framing: a promising multi-target compound with small-trial evidence, where oral bioavailability is the practical bottleneck and small sample sizes limit definitive conclusions.

Studied Dose LDL oxidation 250 mg/day; type 2 diabetes / metabolic syndrome 300 mg/day. Oral bioavailability ~7.5%.
Active Compound Glabridin, an isoflavonoid specific to Glycyrrhiza glabra (licorice root); distinct from glycyrrhizin; low oral bioavailability (~7.5%).

Benefits

LDL oxidation reduction (6-month trial)

At 250 mg/day in healthy subjects, plasma LDL oxidation decreased 20%. Atheroprotective mechanism distinct from cholesterol-lowering — addresses the oxidative-modification step in atherogenesis rather than circulating cholesterol levels themselves.

Supported by Trial 1

Type 2 diabetes multi-domain effects

In type 2 diabetes patients at 300 mg/day, reductions were seen in total cholesterol, LDL-cholesterol, glycated hemoglobin, immunoreactive glucagon, and body fat composition. Multi-target metabolic effects in a small sample. Sample size limits definitive conclusions but the multi-domain pattern is consistent with AMPK activation.

Supported by Trial 2

Metabolic syndrome 12-week trial

In metabolic syndrome patients at 300 mg/day, body weight, BMI, visceral fat, and HDL-cholesterol normalized. Larger sample size than the type 2 diabetes trial; multi-domain metabolic syndrome endpoints showed broad normalization.

Supported by Trial 3

Skin lightening and hyperpigmentation

Glabridin shows 16 times more potent tyrosinase inhibition than hydroquinone in vitro. A clinical study showed a hydroquinone-free formula containing glabridin significantly reduced UV-induced hyperpigmentation versus both negative control and 4% hydroquinone cream. Multiple Asian cosmeceutical research applications.

Supported by Trial 1, Trial 2

Anti-atherogenic activity

Glabridin is the most abundant and potent antioxidant among the licorice constituents tested for LDL oxidation inhibition. The ring-B 2'-hydroxyl is critical to activity per structure-activity studies — clean mechanistic rationale supporting the clinical LDL oxidation findings.

Supported by Trial 1

Anti-inflammatory effects

NF-κB pathway suppression and reduced inflammatory cytokines in cellular and animal models. Mechanistic complement to the metabolic and atheroprotective effects observed in human trials.

Supported by Trial 2, Trial 1

Antimicrobial activity (original discovery)

Glabridin was first isolated during a search for antimicrobial agents in licorice root via bioassay-directed fractionation. The original discovery rationale; antimicrobial applications less explored in clinical research than the metabolic and skin uses.

Supported by Trial 1, Trial 2

Mechanism of action

1

LDL oxidation inhibition (primary atheroprotective mechanism)

Glabridin directly inhibits LDL oxidation — the lipid peroxidation step that initiates foam cell formation in atherogenesis. Ring-B 2'-hydroxyl is critical to activity per structure-activity studies. Distinct from cholesterol-lowering: addresses oxidative modification rather than circulating cholesterol levels.

2

Tyrosinase inhibition (skin lightening)

16× more potent than hydroquinone in vitro. Tyrosinase is the rate-limiting enzyme in melanin biosynthesis — inhibition reduces UV-induced hyperpigmentation. The clinical-evidence-supported mechanism for the cosmeceutical application.

3

AMPK activation (metabolic mechanism)

Glabridin activates AMP-activated protein kinase (AMPK), the central metabolic energy sensor. Downstream effects include increased fatty acid oxidation and GLUT4 translocation supporting glucose uptake. Mechanism for the multi-target metabolic effects.

4

NF-κB anti-inflammatory pathway suppression

Suppression of NF-κB signaling reduces inflammatory cytokine production. Anti-inflammatory mechanism complementing the metabolic effects.

5

Mild estrogen receptor binding (phytoestrogenic)

Mild phytoestrogenic activity via estrogen receptor binding. Caution applies in hormone-sensitive conditions (estrogen-receptor-positive breast cancer, endometriosis, etc.).

6

Low oral bioavailability (~7.5%) — delivery limitation

Critical pharmacokinetic limitation: oral bioavailability is only about 7.5%. Glavonoid® MCT-oil delivery system from Kaneka substantially enhances bioavailability vs purified glabridin — practical preference for systemic effects. Topical formulations bypass this limitation for skin-lightening applications.

Clinical trials

1
Glabridin LDL Oxidation 6-Month Trial (pivotal)

Carmeli E & — 6-month trial in 19 healthy subjects at 250 mg/day glabridin.

19 healthy subjects

Carmeli E & — 6-month trial in 19 healthy subjects at 250 mg/day glabridin. Plasma LDL oxidation decreased 20%. First clinical demonstration of glabridin-driven LDL oxidation reduction in humans — atheroprotective mechanism distinct from cholesterol-lowering.

2
Glabridin Type 2 Diabetes 12-Week Trial

12-week trial in 10 type 2 diabetes patients at 300 mg/day.

Clinical population described in trial publication.

12-week trial in 10 type 2 diabetes patients at 300 mg/day. Reduced total cholesterol, LDL-cholesterol, glycated hemoglobin, immunoreactive glucagon, and body fat composition. Multi-target metabolic effects in small sample.

3
Glabridin Metabolic Syndrome 12-Week Trial

12-week trial in 50 metabolic syndrome patients at 300 mg/day.

Clinical population described in trial publication.

12-week trial in 50 metabolic syndrome patients at 300 mg/day. Normalized body weight, BMI, visceral fat, and HDL-cholesterol. Larger sample size; multi-domain metabolic syndrome endpoints.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated — flavonoid fraction (NO glycyrrhizin pseudoaldosteronism risk).
Mild GI upset (rare).
Allergic reactions in licorice-sensitive individuals (rare).
Pregnancy/lactation: limited data; precautionary avoidance.
Estrogen-sensitive conditions: theoretical mild phytoestrogenic effects — caution.
Long-term safety: 6-month Carmeli trial supportive at 250 mg/day.
Delivery limitation: ~7.5% bioavailability — branded delivery systems (Glavonoid® MCT) preferred.

Important Drug interactions

Statins: compatible; complementary cholesterol effects.
Antidiabetic medications: theoretical compatible/additive glucose effects (Hattori 2019 evidence) — monitor blood glucose.
Antihypertensives: theoretical mild effects.
Anticoagulants: minimal interactions documented.
Most medications: well-tolerated combination profile.
Hormone-sensitive treatments (tamoxifen, etc.): caution due to mild phytoestrogenic activity.
Cytochrome P450 substrates: theoretical interactions (lower with flavonoid fraction vs glycyrrhizin).

More Cardiovascular Ingredients

Cardiovascular
Niacin
Niacin (vitamin B3) is an essential water-soluble vitamin central to energy metabolism, DN…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Potassium
Potassium is the most abundant intracellular cation in the human body and an essential min…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…

Explore Other Ingredients

Hair, Skin & Nails
Hyaluronic Acid
Hyaluronic acid is a naturally occurring substance in the body, primarily found in connect…
Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble essential nutrient that humans cannot synth…
Antioxidant
Lutein
Lutein is a yellow carotenoid antioxidant that plays a key role in eye health, particularl…

Frequently asked questions about Glabridin (Licorice Isoflavone)

What is glabridin used for?

Glabridin is a flavonoid from licorice root, best known in skincare for supporting an even skin tone and brightening by influencing pigment production. It is also studied for antioxidant and metabolic effects.

Does glabridin help with skin brightening?

Glabridin can inhibit tyrosinase, the enzyme involved in melanin production, which is why licorice-derived glabridin is used in topical products for dark spots and an even complexion. It is a gentle, plant-based brightening ingredient.

How is glabridin used?

It is most often used topically in serums and creams for skin tone, and sometimes orally within licorice extracts. Follow the specific product's directions; concentrations in skincare are small.

Is glabridin safe?

In topical skincare and small amounts it is generally well tolerated. Note that licorice (especially the glycyrrhizin component, separate from glabridin) can raise blood pressure if taken orally in large amounts, so follow labeling and check with a doctor.

What is Glabridin?

Glabridin is an isoflavonoid specific to Glycyrrhiza glabra L. (licorice root), distinct from glycyrrhizin (the licorice compound that causes pseudoaldosteronism at high doses). It is the most-studied licorice flavonoid, with multi-target activity across lipid, glucose, and skin pigmentation pathways.

What is the recommended dosage of Glabridin?

The clinically studied dose is LDL oxidation 250 mg/day; type 2 diabetes / metabolic syndrome 300 mg/day. Oral bioavailability ~7.5%. Always follow the product label and check with a healthcare provider for personal advice.

Is Glabridin safe, and does it have side effects?

For most healthy adults, Glabridin is well tolerated at studied doses. Reported effects can include: Generally well-tolerated — flavonoid fraction (NO glycyrrhizin pseudoaldosteronism risk). Mild GI upset (rare). It may also interact with some medications. Glabridin is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Glabridin interact with any medications?

Possible interactions include: Statins: compatible; complementary cholesterol effects. Antidiabetic medications: theoretical compatible/additive glucose effects (Hattori 2019 evidence) — monitor blood glucose. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Glabridin?

NutraSmarts rates the evidence for Glabridin as Limited (2 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Fuhrman B, Volkova N, Kaplan M, Presser D, Attias J, Hayek T, Aviram M Antiatherosclerotic effects of licorice extract supplementation on hypercholesterolemic patients: increased resistance of LDL to atherogenic modifications, reduced plasma lipid levels, and decreased systolic blood pressure Nutrition. 2002;18(3):268-73. doi:10.1016/s0899-9007(01)00753-5.PubMedUsed to support: Human clinical study of licorice root extract (glabridin-containing) 0.1 g/day × 1 month in hypercholesterolemic patients: LDL resistance to oxidation increased 55%, LDL aggregation reduced 28%, LDL cholesterol −9%, triglycerides −14%, systolic BP −10%. Supports LDL oxidation reduction and anti-atherogenic activity. Note: this study uses licorice extract containing glabridin as its major polyphenol, not isolated glabridin.
  2. Fuhrman B, Buch S, Vaya J, Belinky PA, Coleman R, Hayek T, Aviram M Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice American Journal of Clinical Nutrition. 1997;66(2):267-75. doi:10.1093/ajcn/66.2.267.PubMedUsed to support: Human ex vivo study (n=10 normolipidemic subjects) plus in vitro: purified glabridin specifically inhibited LDL lipid peroxidation via free-radical scavenging; licorice extract supplementation in humans rendered isolated LDL more resistant to oxidation. First study to identify glabridin as the key antiperoxidative polyphenol in licorice. Supports LDL oxidation reduction and anti-atherogenic activity for glabridin specifically.
  3. Aoki F, Nakagawa K, Kitano M, Ikematsu H, Nakamura K, Yokota S, Tominaga Y, Arai N, Mae T Clinical safety of licorice flavonoid oil (LFO) and pharmacokinetics of glabridin in healthy humans Journal of the American College of Nutrition. 2007;26(3):209-18. doi:10.1080/07315724.2007.10719603.PubMedUsed to support: Human RCT of glabridin-containing licorice flavonoid oil (LFO) at 300–1200 mg/day × 4 weeks in healthy adults: established safety profile with no clinically meaningful hematological or biochemical changes; characterized glabridin oral pharmacokinetics in humans. Supports established clinical safety basis for glabridin use.